Mumbai, March 06, 2025 – Parexel, one of the world’s largest clinical research organizations (CROs) providing
the full range of Phase I to IV clinical development services, today announced the appointment of Jeff
Bernstein, Partner, Private Equity, Goldman Sachs Asset Management, and Co-Head, Goldman Sachs
Healthcare Private Equity Investing, to its Board of Directors effective March 5, 2025. Mr. Bernstein succeeds
Michael Bruun, Partner, Global Co-Head of Private Equity, Goldman Sachs Asset Management, as part of a
planned rotation.

“Michael Bruun has been a tremendous asset to our Board over the past two years and we’re incredibly
grateful for his engagement, guidance, and leadership,” said Peyton Howell, Chief Executive Officer. “We thank
Michael for his service and wish him the very best in his future endeavors.”

She continued, “We’re delighted to welcome Jeff Bernstein to the Parexel Board. His deep knowledge across
the global financial and healthcare landscape will be invaluable as we work to create even greater value for
our stakeholders in 2025 by leveraging unique insights, driving best-in-class delivery, and building trust to
achieve market-leading growth.”

Mr. Bernstein brings significant healthcare investment, financial and public company Board expertise to
Parexel. He joined Goldman Sachs as an Analyst in 2008, was named Managing Director in 2019, and made
Partner in 2024.

Sheri McCoy, Chairperson of the Board, added, “Jeff’s extensive background in healthcare will be a great asset to the Board as we prepare for the next phase of Parexel’s growth. We look forward to leveraging his insights as we work to advance our strategic roadmap and deliver on our growth objectives.”

Mr. Bernstein currently serves on the boards of Advanced Recovery Systems, AvaSure, Capital Vision Services
(referred to publicly as MyEyeDr.) and MDVIP. He previously served on the boards of several other healthcare
companies, including Brighton Health Plan Solutions, Privia Health Grou,p, and Upstream Rehabilitation. Mr.
Bernstein earned a Bachelor of Arts in Economics and a certificate in Finance from Princeton University.

“I’m extremely pleased to join Parexel’s Board,” said Mr. Bernstein. “I look forward to supporting the company
as it differentiates and innovates to advance its position as a leading global CRO and accelerate the delivery of
life-enhancing new therapies to patients worldwide.”